ZA200905306B - Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity - Google Patents

Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity

Info

Publication number
ZA200905306B
ZA200905306B ZA200905306A ZA200905306A ZA200905306B ZA 200905306 B ZA200905306 B ZA 200905306B ZA 200905306 A ZA200905306 A ZA 200905306A ZA 200905306 A ZA200905306 A ZA 200905306A ZA 200905306 B ZA200905306 B ZA 200905306B
Authority
ZA
South Africa
Prior art keywords
treatment
urinary tract
overactive bladder
lower urinary
tract symptoms
Prior art date
Application number
ZA200905306A
Other languages
English (en)
Inventor
Juergen Engel
Oliver Bauer
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of ZA200905306B publication Critical patent/ZA200905306B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA200905306A 2007-03-05 2009-07-30 Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity ZA200905306B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07103483A EP1967202A1 (en) 2007-03-05 2007-03-05 Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity

Publications (1)

Publication Number Publication Date
ZA200905306B true ZA200905306B (en) 2010-04-28

Family

ID=38006763

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905306A ZA200905306B (en) 2007-03-05 2009-07-30 Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity

Country Status (13)

Country Link
US (1) US20090075937A1 (xx)
EP (2) EP1967202A1 (xx)
JP (1) JP2010520257A (xx)
KR (1) KR20100014923A (xx)
CN (1) CN101657211A (xx)
AU (1) AU2008223841A1 (xx)
BR (1) BRPI0808488A2 (xx)
CA (1) CA2679690A1 (xx)
IL (1) IL200182A0 (xx)
MX (1) MX2009009320A (xx)
RU (1) RU2009136642A (xx)
WO (1) WO2008107446A1 (xx)
ZA (1) ZA200905306B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240697A1 (en) 2007-11-02 2010-09-23 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
WO2010118291A2 (en) 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
CN105663059A (zh) 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
EP2266568A1 (en) * 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266567A1 (en) * 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
MX353105B (es) * 2010-08-03 2017-12-19 Velicept Therapeutics Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva.
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
RS55457B1 (sr) 2010-10-27 2017-04-28 Ferring Bv Postupak za proizvodnju degareliksa i njegovih intermedijara
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
RU2657444C2 (ru) 2012-06-01 2018-06-13 Ферринг Б.В. Получение дегареликса
EP2897616A1 (en) 2012-09-18 2015-07-29 TARIS Biomedical LLC Drug delivery systems and methods for treatment of bladder voiding dysfunction!and other lower urinary tract disorders by using trospium
AU2015358378A1 (en) 2014-12-03 2017-06-29 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
CN1879630A (zh) * 1998-06-11 2006-12-20 内部研究股份有限公司 雄－5－烯－3β,17β－二醇的药物组合物及其用途
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
NZ533430A (en) * 2001-12-14 2005-12-23 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
DE102004033902A1 (de) * 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)

Also Published As

Publication number Publication date
CN101657211A (zh) 2010-02-24
JP2010520257A (ja) 2010-06-10
CA2679690A1 (en) 2008-09-12
RU2009136642A (ru) 2011-04-10
KR20100014923A (ko) 2010-02-11
BRPI0808488A2 (pt) 2014-07-15
AU2008223841A1 (en) 2008-09-12
US20090075937A1 (en) 2009-03-19
EP2131854A1 (en) 2009-12-16
IL200182A0 (en) 2010-04-15
WO2008107446A1 (en) 2008-09-12
MX2009009320A (es) 2009-09-10
EP1967202A1 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
IL200182A0 (en) Use of lhrh antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity
AP2011005672A0 (en) Pyrazolopyrimidines and their use for the treatment of CNS disorders.
HK1222326A1 (zh) 來自胎盤組織的粘附細胞及其在治療中的用途
PT2162118T (pt) Microesferas porosas e sua utilização em terapia
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
IL181369A0 (en) Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
PL2087094T3 (pl) Lactobacillus fermentum ess-1, dsm17851 i jego zastosowanie do leczenia i/lub zapobiegania kandydozie i zakażeniom dróg moczowych
PT2026821E (pt) Misturas binárias de ácido hialurónico e uso terapêutico das mesmas
IL198461A (en) 3 alpha androstandiol and type 5 phosphodiesterase inhibitor (pde5 for on-demand use in the treatment of sexual dysfunction
AU2008233232A8 (en) Combination therapy for the treatment-of Lower Urinary Tract Symptoms
IL215583A0 (en) Methods for preventing and/or treating lysosomal storage disorders
IL204990A0 (en) Use of 3,11 b-cis - dihydrotetrabenazine in the treatment of multiple sclerosis and autoimmune myelitis
HK1150401A1 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
PL2251016T3 (pl) Miejscowe zastosowanie kwasu hialuronowego o działaniu filmotwórczym do leczenia i profilaktyki schorzeń dróg oddechowych
GB0908868D0 (en) Depsipeptide and their therapeutic use
GB2460181B (en) Depsipeptides and their therapeutic use
IL199214A0 (en) New combination for use in the treatment of inflammatory disorders
IL208385A0 (en) Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
EP2313165A4 (en) BALL FOR PLAY AND / OR TRAINING
EP2121785A4 (en) SYDNONIMINES - INHIBITORS FOR SPECIFIC DOPAMINE REABSORPTION AND THEIR USE IN THE TREATMENT OF DOPAMINE-RELATED DISORDERS
PL2327407T3 (pl) Środek profilaktyczny i/lub terapeutyczny na zaburzenia czynnościowe przewodu pokarmowego
GB0718824D0 (en) Methods of treating lysosomal storage disorders